CHMFL-EGFR-202
CHMFL-EGFR-202 is a potent, irreversible EGFR kinase inhibitor, effective against both wild-type and drug-resistant T790M mutant forms with IC50 values of 8.3 nM and 5.3 nM, respectively. It is a valuable research tool for in vitro and in vivo studies targeting EGFR-driven cancers, including non-small cell lung cancer.
Product Specifications
CAS Number
2089381-40-6
Product Name Alternative
CHMFL EGFR 202, CHMFL-EGFR 202, CHMFLEGFR202, CHMFL-EGFR202, CHMFL-EGFR-202, BMX, Btk, BLK, ErbB4, ErbB2, EGFR, EGFRT790M, MEK1
Field of Research
Cardiovascular Research, Cell Biology, Signal Transduction
Purity
99.19% (May vary between batches)
Solubility
DMSO:45 mg/mL (91.84 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.08 mM)
Smiles
NC1=C2C (=NN (C2=NC=N1) [C@H]3CN (C (C=C) =O) CCC3) C4=CC (Cl) =C (OCC5=CC=CC=N5) C=C4
Molecular Formula
C25H24ClN7O2
Molecular Weight
489.96
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
KLF13 (Kruppel-like Factor 13, Basic Transcription Element Binding Protein 3, BTE Binding Protein 3, BTEB3, FKLF2, Novel Sp1-like Zinc Finger Transcription Factor, NSLP1, RANTES Factor of Late Activated T Lymphocytes 1, RFLAT1, Transcription Factor NSLP1) discontinued
KLF13 (Kruppel-like Factor 13, Basic Transcription Element Binding Protein 3, BTE Binding Protein 3, BTEB3, FKLF2, Novel Sp1-like Zinc Finger Transcription Factor, NSLP1, RANTES Factor of Late Activated T Lymphocytes 1, RFLAT1, Transcription Factor NSLP1) discontinued
